anti-CD40L antibody frexalimab which is in mid-stage testing for multiple sclerosis, and SAR441566, an orally-active TNF blocker that Sanofi thinks could be the biggest drug it has ever developed.

Other CD40L-directed therapies in the industry pipeline include Sanofi's frexalimab – in phase 3 for multiple sclerosis and phase 2 for SLE and type 1 diabetes – and Novartis' iscalimab ...

Royalty Pharma's Q3 results met expectations, with a modest 2024 outlook increase, driven by strong portfolio performance and new royalty acquisitions. The CF franchise remains a key cash cow ...

Dimitrios Karussis, Department of Neurology, Laboratory of Neuroimmunology and the Agnes Ginges Center for Neurogenetics, Hadassah-Hebrew University Center, Jerusalem, Ein-Karem, IL-91120, Israel ...

Uveitis is uncommon in patients with multiple sclerosis (MS), but the link between the two entities is clearly established. While a common etiology or pathologic process remains unknown, shared ...

Sanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 14,385.85 Crore) operating in Pharmaceuticals sector. Sanofi India Ltd. key Products/Revenue Segments ...